SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

AstraZeneca shares rise after Phase 3 Tagrisso win

AstraZeneca (NYSE:AZN) priced its stock at $161.62 after reporting another Phase 3 victory Tuesday, saying Tagrisso plus Orpathys from Hutchmed delayed disease progression versus Tagrisso alone in previously untreated patients.

AZN

AstraZeneca NYSE:AZN said Tuesday that Tagrisso combined with Hutchmed's Orpathys significantly delayed disease progression versus Tagrisso alone in previously untreated patients. The stock was priced at $161.62. The result was a Phase 3 win.

Related stories